Yes, it’s not too late to wish you the best for this new year. For us, 2021 was a very dense year with many collaborative projects, especially to expand the use of BIOMIMESYS©, our innovation 3D cell culture technology, in several domains like cancer treatments or neurodegenerative diseases studies. We also worked hard to develop the company in Asia with our amazing distributors Tokyo Future Style Taiwan, Inc (Taiwan) and JVCKENWOOD Corporation (Japan).

We are starting 2022 with ambitious projects. We work to develop artificial intelligence algorithms for the exploitation of 3D images. Our preliminary results are very promising (the scientific paper will be published soon) and we hope to present a new method during 2022.

We conduct a big study on the impact of the rigidity of tumor Extra-Cellular Matrix. We knew the importance of the increase of TECM stiffness in tumorigenesis since years, but soon we will be able to quantify this influence in order to develop new 3D cellular models for pre-clinical research.

We also work on advanced biological models including microfluidics and BIOMIMESYS© to be even closer to real human body conditions in drugs discovery testing. Stay tuned!

We hope 2021 has been a good year for you too, despite the still complicated situation. If you would like to take some time to discuss the opportunities of the coming year with 3D cell culture, we are at your disposal.

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.